Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Michael Kauffman Stories

2013-04-30 12:27:08

Industry Veteran to Lead Metamark Genetics in Commercialization of Novel Prognostic Tests for Prostate and Other Cancers CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Metamark Genetics, Inc., a leader in the discovery of novel molecular prognostic and diagnostic tests for cancer, today announced that industry veteran Shawn M. Marcell has been named the company's new president and chief executive officer. Mr. Marcell succeeds interim executive Michael Kauffman, M.D., who will...

2012-10-31 15:25:15

NATICK, Mass., Oct. 31, 2012 /PRNewswire/ -- Ronald A. DePinho, M.D., a co-founder and board member of Karyopharm Therapeutics Inc. since 2009, elected to resign from the company's board of directors, effective Oct. 10, 2012, at a time when the company has achieved a "strong base of operations." "I am proud of the stellar group of physicians and scientists at Karyopharm who are focused on the needs of cancer patients," Dr. DePinho said. "With the transition of its nuclear transport...

2011-11-02 07:00:00

NATICK, Mass., Nov. 2, 2011 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, has completed a $10M Series A2 financing which complements the $20M Series A financing announced one year ago. Both Series A and A2 were lead by Chione Ltd. This brings the total raised by the Company to approximately $32M since its inception. The funds will be used to expand the planned Phase I program, targeted to begin in mid 2012 with Karyopharm's oral...

2010-02-01 10:15:00

EMERYVILLE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has appointed Ted W. Love, M.D., Executive Vice President and Head of Research and Development. In addition, Michael Kauffman, M.D., Ph.D., who has served as Interim Chief Medical Officer since November 2009, has been appointed Chief Medical Officer reporting to Dr. Love. In his new role, Dr. Love will report to the Chief Executive Officer and will be responsible for...

2008-07-29 06:00:47

Epix Pharmaceuticals has announced that Michael Kauffman has resigned his position as CEO and director, to pursue other opportunities. Mr Kauffman joined Epix in August 2006 in connection with its acquisition of Predix Pharmaceuticals Holdings, where he had served as CEO since September 2002. Epix also named his replacement with the appointment of Elkan Gamzu, as interim CEO. Mr Gamzu is currently a consultant to the biotechnology and pharmaceutical industries and has held a number of...